{"id":33030,"date":"2023-05-12T12:34:13","date_gmt":"2023-05-12T10:34:13","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=33030"},"modified":"2023-05-12T12:35:54","modified_gmt":"2023-05-12T10:35:54","slug":"therapierefraktaere-depression-im-alter-die-optimum-studie-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2023\/therapierefraktaere-depression-im-alter-die-optimum-studie-cme","title":{"rendered":"Therapierefrakt\u00e4re Depression im Alter: die OPTIMUM-Studie [CME]"},"content":{"rendered":"<p>Eine Depression hat oft neben dem Verlust an Aktivit\u00e4t und Lebensfreude noch andere nachteilige Folgen wie beispielsweise die Abnahme kognitiver F\u00e4higkeiten und ein erh\u00f6htes Sturzrisiko, besonders im Alter. Etwa 30% der Patienten, die medikament\u00f6s behandelt werden, sprechen nicht auf \u00fcbliche Antidepressiva (AD) wie selektive Serotonin-Reuptake-Inhibitoren (SSRI) an . Zur Therapie-Eskalation empfiehlt die Nationale Versorgungsleitlinie (NVL) [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eine Depression hat oft neben dem Verlust an Aktivit\u00e4t und Lebensfreude noch andere nachteilige Folgen wie beispielsweise die Abnahme kognitiver F\u00e4higkeiten und ein erh\u00f6htes Sturzrisiko, besonders im Alter. Etwa 30% der Patienten, die medikament\u00f6s behandelt werden, sprechen nicht auf \u00fcbliche Antidepressiva (AD) wie selektive Serotonin-Reuptake-Inhibitoren (SSRI) an . Zur Therapie-Eskalation empfiehlt die Nationale Versorgungsleitlinie (NVL) [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[349,909,2118,1254,5841,2574,2120,5840,5842],"class_list":["post-33030","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alter","tag-aripiprazol","tag-bupropion","tag-depression","tag-irl-grey-studie","tag-lithium","tag-nortriptylin","tag-optimium-studie","tag-star-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/33030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=33030"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/33030\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=33030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=33030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=33030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}